pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs
- PMID: 10796075
- DOI: 10.1016/s0006-2952(99)00021-0
pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs
Abstract
Resistance to chemotherapeutic agents is a major cause of treatment failure in patients with cancer. The primary mechanism leading to a multidrug-resistant phenotype is assumed to be plasma-membrane localized overexpression of drug efflux transporters, such as P-glycoprotein (P-gp). However, acidic intracellular organelles can also participate in resistance to chemotherapeutic drugs. In this study, we investigated, both experimentally and theoretically, the effect of acidic vesicle turnover on drug resistance. We have developed a general model to account for multiple mechanisms of resistance to weakly basic organic cations, e.g. anthracyclines and Vinca alkaloids. The model predicts that lower cytosolic concentrations of drugs can be achieved through a combination of high endosomal turnover rates, a low endosomal pH, and an alkaline-inside pH gradient between cytosol and the extracellular fluid. Measured values for these parameters have been inserted into the model. Computations using conservative values of all parameters indicate that turnover of acidic vesicles can be an important contributor to the drug-resistant phenotype, especially if vesicles contain an active uptake system, such as H+/cation exchange. Even conservative estimates of organic cation-proton antiport activity would be sufficient to make endosomal drug extrusion a potent mechanism of resistance to weakly basic drugs. The effectiveness of such a drug export mechanism would be comparable to drug extrusion via drug pumps such as P-gp. Thus, turnover of acidic vesicles can be an important factor in chemoresistance, especially in cells that do not overexpress plasma membrane-bound drug pumps like P-glycoprotein.
Similar articles
-
pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines.Biochem Pharmacol. 1999 May 1;57(9):1037-46. doi: 10.1016/s0006-2952(99)00022-2. Biochem Pharmacol. 1999. PMID: 10796074
-
Proton pump inhibitors may reduce tumour resistance.Expert Opin Pharmacother. 2005 Jun;6(7):1049-54. doi: 10.1517/14656566.6.7.1049. Expert Opin Pharmacother. 2005. PMID: 15957961 Review.
-
Resistance mechanisms associated with altered intracellular distribution of anticancer agents.Pharmacol Ther. 2000 Mar;85(3):217-29. doi: 10.1016/s0163-7258(99)00073-x. Pharmacol Ther. 2000. PMID: 10739876 Review.
-
Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.Oncotarget. 2016 Sep 27;7(39):63408-63423. doi: 10.18632/oncotarget.11503. Oncotarget. 2016. PMID: 27566564 Free PMC article.
-
Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.J Bone Joint Surg Am. 2000 Jul;82-A(7):963-9. doi: 10.2106/00004623-200007000-00008. J Bone Joint Surg Am. 2000. PMID: 10901311
Cited by
-
Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer.J Exp Clin Cancer Res. 2015 Aug 22;34(1):85. doi: 10.1186/s13046-015-0194-x. J Exp Clin Cancer Res. 2015. PMID: 26297142 Free PMC article. Clinical Trial.
-
Causes and effects of heterogeneous perfusion in tumors.Neoplasia. 1999 Aug;1(3):197-207. doi: 10.1038/sj.neo.7900037. Neoplasia. 1999. PMID: 10935474 Free PMC article. Review.
-
Physiological and pathophysiological role of ion channels and transporters in the colorectum and colorectal cancer.J Cell Mol Med. 2020 Sep;24(17):9486-9494. doi: 10.1111/jcmm.15600. Epub 2020 Jul 13. J Cell Mol Med. 2020. PMID: 32662230 Free PMC article. Review.
-
Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma.Cancer Prev Res (Phila). 2014 Dec;7(12):1258-69. doi: 10.1158/1940-6207.CAPR-14-0002. Cancer Prev Res (Phila). 2014. PMID: 25468899 Free PMC article.
-
A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment.Funct Integr Genomics. 2023 May 26;23(2):182. doi: 10.1007/s10142-023-01117-w. Funct Integr Genomics. 2023. PMID: 37231285 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous